Lauren P. Silvernail
2016
In 2016, Lauren P. Silvernail earned a total compensation of $1.5M as Chief Financial Officer and Chief Business Officer at Revance Therapeutics, a 42% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $157,219 |
|---|---|
| Option Awards | $689,334 |
| Salary | $430,000 |
| Stock Awards | $203,200 |
| Other | $64,643 |
| Total | $1,544,396 |
Silvernail received $689.3K in option awards, accounting for 45% of the total pay in 2016.
Silvernail also received $157.2K in non-equity incentive plan, $430K in salary, $203.2K in stock awards and $64.6K in other compensation.
Rankings
In 2016, Lauren P. Silvernail's compensation ranked 6,102nd out of 14,075 executives tracked by ExecPay. In other words, Silvernail earned more than 56.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,102 out of 14,075 | 57th |
Division Manufacturing | 2,227 out of 5,486 | 59th |
Major group Chemicals And Allied Products | 730 out of 1,900 | 62nd |
Industry group Drugs | 551 out of 1,543 | 64th |
Industry Pharmaceutical Preparations | 431 out of 1,173 | 63rd |
Source: SEC filing on March 24, 2017.
Silvernail's colleagues
We found two more compensation records of executives who worked with Lauren P. Silvernail at Revance Therapeutics in 2016.